Digital biology company Optic is collaborating with early-stage oncology therapeutics venture, Vindur Tx, to use Optics proprietary generative AI platform to find novel highly selective kinase inhibitors and develop more effective cancer treatments.
Vindur Tx agreed to pay Optic as much as $17.5 million for its proprietary technology to search for new ways of addressing what the company called...
